HBV核心相关抗原对PEG-IFNα治疗HBeAg阳性慢性乙型肝炎患者效果的预测价值

王晴; 许志强; 刘瑞霞; 傅涓涓; 李丽; 潘修成

doi:10.3969/j.issn.1001-5256.2018.09.011

HBV核心相关抗原对PEG-IFNα治疗HBeAg阳性慢性乙型肝炎患者效果的预测价值

DOI: 10.3969/j.issn.1001-5256.2018.09.011

徐州医科大学附属医院感染性疾病科

基金项目:

江苏省临床医学科技专项基金资助(BL2012043)；

详细信息

中图分类号: R512.62
计量
- 文章访问数: 2716
- HTML全文浏览量: 40
- PDF下载量: 360
- 被引次数: 0
出版历程
- 收稿日期: 2018-03-01
- 出版日期: 2018-09-20

Value of serum hepatitis B virus core-related antigen in predicting the treatment outcome of HBeAg-positive chronic hepatitis B patients treated with pegylated interferon-α

Department of Infectious Diseases, The Affiliated Hospital of Xuzhou Medical University

Research funding:

摘要

摘要: 目的评价HBV核心相关抗原（HBcrAg）对HBeAg阳性慢性乙型肝炎患者PEG-IFNα治疗效果的预测价值。方法选取2012年5月-2015年6月在徐州医科大学附属医院感染科接受PEG-IFNα治疗的HBeAg阳性慢性乙型肝炎患者79例,疗程48周,疗程结束后随访至少24周。分别检测治疗前以及治疗12周、24周、48周时HBcrAg、HBV血清标志物、HBV DNA以及ALT水平。服从正态分布的计量资料组间比较采用t检验,非正态分布的计量资料组间比较采用Mann-Whitney U检验;计数资料组间比较采用χ2或Fisher确切概率法,相关性分析采用Pearson相关分析,采用二分类logistic回归分析筛选完全应答的影响因素;采用受试者工作特征曲线判断HBcrAg对实现完全应答的预测价值。结果 79例接受PEG-IFNα抗病毒治疗的HBeAg阳性慢性乙型肝炎患者治疗结束后随访24周,35例实现了完全应答。应答组相较于非应答组具有更低的基线HBsAg水平（P=0.008）、HBeAg水平（P<0.001）以及HBcrAg水平（P=0.002）。基线HBcrAg与HBV DNA...
- 肝炎,乙型,慢性 /
- 乙型肝炎核心相关抗原 /
- 聚乙二醇干扰素-α /
- 治疗结果
Abstract: Objective To investigate the value of hepatitis B virus core-related antigen (HBcrAg) in predicting the treatment outcome of HBeAg-positive chronic hepatitis B (CHB) patients treated with pegylated interferon-α (PEG-IFNα) . Methods A total of 79 HBeAg-positive CHB patients who were treated with PEG-IFNα in Department of Infectious Diseases in The Affiliated Hospital of Xuzhou Medical University from May 2012 to June 2015 were enrolled. The course of treatment was 48 weeks, and the patients were followed up for at least 24 weeks after treatment. HBcrAg, HBV serum markers, HBV DNA, and alanine aminotransferase (ALT) level were measured before treatment and at weeks 12, 24, and 48 of treatment. The t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups; the chi-square test or the Fisher's exact test was used for comparison of categorical data between groups; a Pearson correlation analysis was performed to investigate correlation; a binary logistic regression analysis was used to identify the influencing factors for complete response; the receiver operating characteristic (ROC) curve was used to investigate the value of HBcrAg in predicting complete response. Results Among the 79 HBeAg-positive CHB patients who were treated with PEG-IFNα antiviral therapy and then followed up for 24 weeks, 35 achieved complete response. Compared with the non-response group, the response group had a significantly lower baseline HBs Ag level (P = 0. 008) , HBeAg level (P < 0. 001) , and HBcrAg level (P = 0. 002) . Baseline HBcrAg was positively correlated with HBV DNA (r = 0. 325, P =0. 003) , HBs Ag level (r = 0. 468, P < 0. 001) , and HBeAg level (r = 0. 695, P < 0. 001) and was not correlated with ALT level. Serum HBcrAg tended to decrease during treatment, and at week 12 of treatment, the response group had a significantly greater reduction in HBcrAg level compared with the non-response group (Z =-2. 653, P = 0. 008) . HBcrAg level at week 12 of treatment was an independent risk factor for complete response (odds ratio = 5. 510, 95% confidence interval: 1. 656-18. 326, P < 0. 05) . The optimal cut-off value of serum HBcrAg was 6. 45 log10 U/ml, and the area under the ROC curve was 0. 845. Conclusion HBcrAg is correlated with HBs Ag, HBeAg, and HBV DNA before PEG-IFNα antiviral therapy. Serum HBcrAg level at week 12 of treatment can be used to predict complete response after PEG-IFNα treatment.
- hepatitis B, chronic /
- hepatitis B virus core-related antigen /
- pegylated interferon-α /
- treatment outcome

HTML全文

参考文献(14)

[1]LIAW YF, KAO JH, PIRATVISUTH T, et al.Asian-Pacific consensus statement on the management of chronic hepatitis B:A 2012 update[J].Hepatol Int, 2012, 6 (3) :531-561.

[2]ASSELAH T, LADA O, MOUCARI R, et al.Interferon therapy for chronic hepatitis B[J].Clin Liver Dis, 2007, 11 (4) :839-849.

[3]SANTANTONIO TA.Chronic hepatitis B:Advances in treatment[J].World J Hepatol, 2014, 6 (5) :284-292.

[4]VLACHOGIANNAKOS J.Optimal therapy of chronic hepatitis B:How do I treat HBe Ag-positive patients?[J].Liver Int, 2015, 35 (Suppl 1) :100-106.

[5]SUZUKI F, MIYAKOSHI H, KOBAYASHI M.Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients[J].JMed Virol, 2009, 81 (1) :27-33.

[6]OKUHARA S, UMEMURA T, JOSHITA S, et al.Serum levels of interleukin-22 and hepatitis B core-related antigen are associated with treatment response to entecavir therapy in chronic hepatitis B[J].Hepatol Res, 2014, 44 (10) :e172-e180.

[7]JIA JD, LI LJ.The guideline of prevention and treatment for chronic hepatitis B[J].J Clin Hepatol, 2011, 27 (1) :113-128. (in Chinese) 贾继东, 李兰娟.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :113-128.

[8]SUNG JJ, WONG ML, BOWDEN S, et al.Intrahepatic hepatitis Bvirus covalently closed circular DNA can be a predictor of sustained response to therapy[J].Gastroenterology, 2005, 128 (7) :1890-1897.

[9]CHEN W, WU F, DOU XG, et al.Analysis of related factors for intrahepatic HBV ccc DNA level in patients with chronic HBV infectio[J].J Clin Hepatol, 2013, 29 (6) :434-437. (in Chinese) 陈嵬, 吴峰, 窦晓光, 等.慢性HBV感染者肝脏HBV ccc DNA含量相关因素分析[J].临床肝胆病杂志, 2013, 29 (6) :434-437.

[10]CHEN EQ, FENG S, WANG ML, et al.Serum hepatitis B corerelated antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B[J].Sci Rep, 2017, 7 (1) :173.

[11]WONG DK, SETO WK, CHEUNG KS, et al.Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA[J].Liver Int, 2017, 37 (7) :995-1001.

[12]MA H, YANG RF, LI XH, et al.HBcr Ag identifies patients failing to achieve HBe Ag seroconversion treated with pegylated interferon alfa-2b[J].Chin Med J (Engl) , 2016, 129 (18) :2212-2219.

[13]CHUAYPEN N, POSUWAN N, PAYUNGPORN S, et al.Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBe Ag-positive chronic hepatitis B[J].Liver Int, 2016, 36 (6) :827-836.

[14]CHUAYPEN N, POSUWAN N, CHITTMITTRAPRAP S, et al.Predictive role of serum HBs Ag and HBcr Ag kinetics in patients with HBe Ag-negative chronic hepatitis B receiving pegylated interferon-based therapy[J].Clin Microbiol Infect, 2017, 24 (3) :306.e7-306.e13.

施引文献

资源附件(0)

访问统计